Tag: breakthrough therapy designation
Prolong’s investigational therapy for acute ischaemic stroke receives US FDA breakthrough...
Prolong Pharmaceuticals has announced that its investigational therapy, pegylated carboxyhaemoglobin bovine (PP-007), has received a breakthrough therapy designation (BTD) from the US Food and...
